Exonate Overview
- Founded
-
2013
- Status
-
Private
- Employees
-
20
- Latest Deal Type
-
Later Stage VC
- Latest Deal Amount
-
$1.9M
- Investors
-
15
Exonate General Information
Description
Provider of biopharmaceutical services intended to improve the treatment of patients with retinal vascular diseases and to transform the lives of those suffering from vision loss. The company's services offer lead program molecules, for wet Age-Related Macular Degeneration (wet AMD), act via a novel mechanism of action to inhibit pathological blood vessels and reduce the formation of pathological Vascular Endothelial Growth Factor without inhibiting beneficial, non-pathological VEGF, enabling doctors to focus on developing novel therapies for wet age-related macular degeneration.
Contact Information
Website
www.exonate.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Pharmaceuticals
Biotechnology
Primary Office
- WTL Moorfield Road
- Duxford
- Cambridge CB22 4PS
- England, United Kingdom
+44 01223 000000
Exonate Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 6. Later Stage VC | 03-Jan-2019 | $1.9M | 00.000 | Completed | Generating Revenue | |
| 5. Later Stage VC | 12-Sep-2018 | 00.000 | 00.000 | 00.000 | Completed | Clinical Trials - Phase 1 |
| 4. Grant | 06-Feb-2017 | 00.000 | 00.000 | Completed | Clinical Trials - Phase 1 | |
| 3. Early Stage VC | 01-Dec-2016 | 00.00 | 00.000 | 00.000 | Completed | Clinical Trials - Phase 1 |
| 2. Early Stage VC | 05-Oct-2015 | $1.21M | $1.87M | 00.000 | Completed | Clinical Trials - Phase 1 |
| 1. Seed Round | 01-Mar-2014 | $651K | $651K | 00.000 | Completed | Clinical Trials - Phase 1 |
Exonate Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Ordinary | 00,000 | 00.000000 | 0000.00 | 0000.00 | 00 | 0000.00 | 00.000 | |
| Ordinary | 00,000 | 00.000000 | 000.00 | 000.00 | 00 | 000.00 | 00.000 | |
| Ordinary | 14,141 | $0.012877 | $72.11 | $72.11 | 1x | $72.11 | 17.79% | |
| Ordinary | 7,860 | $0.012877 | $64.39 | $64.39 | 1x | $64.39 | 9.89% |
Exonate Comparisons
Description
Primary
Industry
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Provider of biopharmaceutical services intended to improve the treatment of patients with retinal vascular diseases and
Drug Discovery
Cambridge, United Kingdom
20
As of 2022
00.000
0000000000 0
00.000
000000
ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse
0000 000000000
London, United Kingdom
000
As of 0000
00000
0.00
0000-00-00
000000&0
00000
000000
nim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequ
0000000000000
Leuven, Belgium
00
As of 0000
0000
000000000
0000
Add Comparison
Exonate Competitors (20)
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Gyroscope | Formerly VC-backed | London, United Kingdom | 000 | 00000 | 000000&0 | 00000 |
| 0000000 | Corporation | Leuven, Belgium | 00 | 0000 | 000000000 | 0000 |
| 00000000 000000 | Formerly VC-backed | Farmington Hills, MI | 0 | 000.00 | 000000000 | 000.00 |
| 000 000000000000 | Venture Capital-Backed | Ann Arbor, MI | 00 | 000.00 | 00000000000 | 000.00 |
| 0000000 0000000000 | Formerly VC-backed | Cambridge, MA | 0000 | 00.000 | 0000 | 00.000 |
Exonate Patents
Exonate Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| GB-202010829-D0 | Compounds for treatment of neovascular diseases | Inactive | 14-Jul-2020 | 0000000000 | |
| GB-201912449-D0 | Compounds for treatment of neovascular diseases | Inactive | 30-Aug-2019 | ||
| GB-201810765-D0 | Srpk1 inhibitors | Inactive | 29-Jun-2018 | ||
| GB-201715637-D0 | Srpk1 inhibitors | Inactive | 27-Sep-2017 | ||
| CA-3077749-A1 | Srpk1 inhibitors | Pending | 27-Sep-2017 | C07D401/12 |
Exonate Executive Team (6)
Exonate Board Members (9)
| Name | Representing | Role | Since |
|---|---|---|---|
| Andrew Garland Ph.D | Self | Board Member | 000 0000 |
| Andrew Naylor | Self | Board Member | 000 0000 |
| Christopher Torrance Ph.D | Self | Board Member | 000 0000 |
| David Bates Ph.D | Exonate | Co-Founder, Chief Scientific Officer and Board Member | 000 0000 |
| John Kurek Ph.D | Uniseed | Board Member | 000 0000 |
Exonate Signals
Growth Rate
0.80%
Weekly
Growth
Growth
Weekly Growth
0.80%, 93rd %
-35.5%.
530%
Size Multiple
219x
Median
Size Multiple
219x, 100th %ile
0.00x
0.95x.
413Kx
Key Data Points
Twitter Followers
5.5k
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
Exonate Investors (15)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|---|---|---|---|---|
| Stoic Venture Capital | Venture Capital | Minority | 000 0000 | 000000 0 | |
| University of Bristol Endowment | Limited Partner | Minority | 000 0000 | 000000 0 | |
| R42 Group | Venture Capital | Minority | 000 0000 | 000000 0 | |
| Wellcome Trust | Limited Partner | 000 0000 | 000000 0 | ||
| Martlet | Venture Capital | Minority | 000 0000 | 000000 0 |